BidaskClub upgraded shares of Novavax (NASDAQ:NVAX) from a hold rating to a buy rating in a research note published on Thursday, March 15th.
Other equities analysts also recently issued reports about the stock. Citigroup upped their price target on shares of Novavax from $2.00 to $2.75 and gave the company a neutral rating in a research note on Wednesday, February 21st. Ladenburg Thalmann restated a buy rating and issued a $3.50 price target on shares of Novavax in a research note on Thursday, March 1st. B. Riley set a $10.00 price target on shares of Novavax and gave the company a buy rating in a research note on Thursday, March 1st. Chardan Capital restated a hold rating on shares of Novavax in a research note on Thursday, March 1st. Finally, Piper Jaffray upped their price target on shares of Novavax to $2.50 and gave the company a neutral rating in a research note on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of $3.43.
Shares of NVAX traded down $0.04 during trading hours on Thursday, hitting $2.02. The company had a trading volume of 4,817,128 shares, compared to its average volume of 6,955,319. The firm has a market capitalization of $694.36, a PE ratio of -3.21 and a beta of 2.38. Novavax has a 12 month low of $0.73 and a 12 month high of $2.75. The company has a debt-to-equity ratio of -3.12, a current ratio of 2.76 and a quick ratio of 2.76.
Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.01). The firm had revenue of $10.40 million for the quarter, compared to the consensus estimate of $7.98 million. Novavax’s revenue for the quarter was up 92.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.21) earnings per share. analysts predict that Novavax will post -0.57 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN grew its stake in Novavax by 30.8% during the third quarter. Wells Fargo & Company MN now owns 446,831 shares of the biopharmaceutical company’s stock worth $509,000 after buying an additional 105,117 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Novavax by 6.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 1,225,018 shares of the biopharmaceutical company’s stock worth $1,397,000 after buying an additional 71,047 shares in the last quarter. Canada Pension Plan Investment Board grew its stake in Novavax by 19.6% during the third quarter. Canada Pension Plan Investment Board now owns 567,800 shares of the biopharmaceutical company’s stock worth $647,000 after buying an additional 92,900 shares in the last quarter. Virtus Fund Advisers LLC acquired a new stake in Novavax during the fourth quarter worth about $329,000. Finally, Virtu Financial LLC grew its stake in Novavax by 11,061.4% during the fourth quarter. Virtu Financial LLC now owns 1,124,842 shares of the biopharmaceutical company’s stock worth $1,395,000 after buying an additional 1,114,764 shares in the last quarter. Hedge funds and other institutional investors own 36.88% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/04/08/bidaskclub-upgrades-novavax-nvax-to-buy.html.
Novavax Company Profile
Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.